Psilocybin Therapy for Depression in Parkinson's Disease

Description

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Conditions

Parkinson Disease, Depression

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Psilocybin Therapy for Depression in Parkinson's Disease

Condition
Parkinson Disease
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 40 to 80
  • * Comfortable speaking and writing in English
  • * Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)
  • * Currently experiencing depressive symptoms
  • * Able to attend all in-person visits at UCSF as well as virtual visits
  • * Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating
  • * Psychotic symptoms involving loss of insight
  • * Significant cognitive impairment
  • * Regular use of medications that may have problematic interactions with psilocybin
  • * A health condition that makes this study unsafe or unfeasible, determined by study physicians

Ages Eligible for Study

40 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Joshua Woolley, MD, PhD,

Joshua Woolley, MD,PhD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Ellen Bradley, MD, STUDY_DIRECTOR, University of California, San Francisco

Study Record Dates

2028-06